NCT04659044 2024-09-19Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaAcademic and Community Cancer Research UnitedPhase 2 Terminated3 enrolled 11 charts